The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 47 | — | 20.1x | Near average | |
Growth | 33 | -13.0% | 5.6% | Below average | |
Quality | 41 | -45.0% | 7.6% | Near average | |
Safety | 52 | 0.4x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Zymeworks Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Zymeworks Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Zymeworks stock has seen a positive revision in its average price target, with the consensus rising by 9.15% to reach $41.75 compared to $38.25 last month, despite the number of analysts remaining steady at 5. This change reflects an upgrade in individual estimates by current analysts, indicating growing optimism regarding the stock's fair value away from the current market price of $24.35.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.